Jayesh Saini and his culture at Dinlas Pharma

Dinlas Pharma, a Kenyan Pharmaceutical Company offers employment opportunities to nurture and develop professional talents towards Government’s main vision in universal health care, manufacturing and job creation, technology among others.

Thanks to Jayesh Saini, the chairman and founder of Dinlas pharma has a new culture that needs to be emulated let alone most staff being youths and women qualified in relevant departments.

Since its inception, Dinlas pharma has been giving back to society through job creation for regular and contractual opportunities to the qualified and competent task forces in the pharmaceutical industry.

The founder and senior director Mr Jayesh Saini has taken a noble initiative of providing the staff members of Dinlas Pharma with complimentary full breakfast, mid-break snack/tea, lunch as well as dinner for those employees working night-shift. The hygienic meals are prepared and served at the company’s canteen.

This initiative has managed to avoid employees getting sick through consuming roadside prepared meals from Kiosks (“vibandas”), thus eliminating the risk of contracting the contagious disease as well as protection against the spread of Covid-19 cases.

Dinlas Pharma is a member of NITA (National Industrial Training Authority) that offers continuous training to our staffs to bridge the gap between skills and experience required for relevant roles in the industry.

Kenya has seen two vaccines namely AstraZeneca, from Serum Institute of India and Sputnik, from the Gamaleya Research Institute. Whilst Sputnik was imported by Dinlas Pharmaceuticals, it was re-exported due to administrative issues.

Dinlas Pharmaceuticals preparedness

Dinlas Pharmaceuticals had prepared themselves for the vaccination drive by having strategies in place for fair distribution and assistance in administration of the Sputnik vaccine. Nurses and healthcare staff across the partner companies of Mr. Jayesh Saini, Kenya; like Bliss Healthcare, Nairobi West Hospital, Clinix Healthcare etc. were specifically trained to administer the jabs manage mass volume of patients.

This was done and signed off by the Ministry of Health (MOH) / Afya house medical team. Mr. Jayesh Saini touched upon his vision behind establishing the state-of-the-art RnD department at Dinlas Pharmaceuticals LTD recently.

In addition to having top-notch manufacturing and packaging machines – it’s equally important to have the above to encourage the team to continue the trials for new molecules 24/7. This remains paramount for the continuously evolving journey of a well-established pharmaceutical setup.

Studies so far says a majority of the risk factors for severe COVID-19 are associated with altered microbiota composition. The underlying impact of microbiome dysbiosis on immunity may not only increase the risk of disease in people in these risk groups but may also affect their response to the COVID-19 vaccines.

Elderly people in care homes have been hit particularly hard by the pandemic, and the vaccine is vital to prevent further outbreaks in such facilities. Immunosenescence is a feature of aging and frailty, which may blunt responsiveness to vaccines and could be driven by dysbiosis.

Also, given the large prevalence of high-risk comorbidities in the general population which features impaired immunity through dysbiosis, there is a risk that a vaccine may not actually be as effective in the real-world setting as it has been shown to be in trials.

Moreover, researchers have suggested that vaccine adverse effects observed in high-risk patients, such as the 23 elderly people who died after receiving an mRNA-based vaccine in Sweden, may have been influenced by dysbiosis.

It is imperative that further research must be conducted to assess vaccine effectiveness in high-risk individuals and better understand the role of the microbiome in influencing response. San Diego, US-based Persephone Biosciences this year initiated the VOICES (Vaccine Observation to Include all Communities for Equitable Science) study in order to find an answer to this important research question, and it is anticipated to complete in late 2022 according to Trialtrove.

 High-risk individuals may benefit from microbiome-modulating therapies to boost their immunity and improve their response to vaccines. If vaccine responsiveness is high for all individuals in a population, herd immunity may be achieved more effectively, and focusing on improving microbiome health may be the key to reaching this goal.

Dinlas Pharma’s Commitment

Dinlas Pharma’s philosophy is to conduct its operations in a manner that is ethical, proactive, environment friendly and sensitive to all its stakeholders. Dinlas Pharma operates in compliance with all regulatory and policy requirements and there are regular audits to ensure that controls and compliances are maintained at a high standard.

With changing global and regional challenges and emerging best practices in the pharmaceutical sector we will update and upgrade our policies and practices at regular intervals. The potential future effects of global climate change are recognized and our efforts are focused on this cause.